Printer Friendly

Bruker Files IPO.

Washington, DC 4/14/00-Bruker Daltonics has filed a S-1 registration statement with the Securities and Exchange Commission to begin trading its stock on the Nasdaq stock exchange under the symbol BDAL. The company expects to raise $125 million in the initial stock sale but gave no details in this filing as to how many shares it plans to sell or the price per share. The company stated that the money raised through the IPO would go towards R&D, expansion, working capital and the repayment of bank loans. In 1999, net revenue for the company was $64.7 million and net income was $1.25 million.

This will give Bruker Daltonics a much needed infusion of cash, but enthusiasm for the stock could be damaged by recent litigation (see below). Bruker has a leading position in MALDI-ToF mass spectrometry with a steadily growing role in ion trap technology. Its recent entrance into the genomics market is very promising but has yet to reap any benefits (see article page 4).
COPYRIGHT 2000 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Instrument Business Outlook
Geographic Code:1USA
Date:Apr 15, 2000
Previous Article:Genetic Patents-Horn of Plenty or Legal Minefield?
Next Article:Bruker Found to Have Infringed Finnigan Patents.

Related Articles
Finnigan Files German Lawsuit Against HP and Bruker.
Bruker's Alliances Set Path for Company's Future.
Going Public Versus Going Private: Companies Take Their Chances.
Random Samples.
Bruker AXS Files IPO.
Bruker Companies and Geneformatics Partner.
Bruker AXS: a company on the move.
Third quarter results look brighter.
Bruker AXS adds to x-ray microanalysis business.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters